文献速递脑血管病

心源性卒中抗凝时机与复发事件风险

Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk.
PubMed 文献 · Ann Neurol · 2020-08-05

该研究基于美国8家卒中中心登记数据,纳入2084例缺血性卒中合并房颤患者中的1289例,比较0-3天、4-14天和>14天启动抗凝的90天复合终点。结果显示三组复合终点无显著差异,推荐4-14天窗口未降低缺血或出血结局。

要点

  • 推荐4-14天启动抗凝未显著降低90天复合终点。
  • 4-14天组症状性颅内出血与0-3天组无显著差异。
  • 4-14天组复发缺血事件与>14天组无显著差异。

核心结论

  • 推荐4-14天启动口服抗凝未与缺血和出血结局降低相关。

研究设计与样本

  • 汇总美国8家综合卒中中心登记数据,纳入连续缺血性卒中合并房颤患者1289例。

主要发现

  • 90天复合终点总发生率10.1%(130例),其中缺血事件87例、症状性颅内出血20例、严重颅外出血29例。
  • 三组复合终点发生率分别为0-3天10.3%(64/617)、4-14天9.7%(52/535)、>14天10.2%(14/137),p=0.933。
  • 校正模型中4-14天组症状性颅内出血与0-3天组比较OR=1.49(95%CI 0.50-4.43)。
  • 4-14天组复发缺血事件与>14天组比较OR=0.76(95%CI 0.36-1.62,p=0.482)。

临床怎么用

  • 真实世界数据提示4-14天抗凝窗口未显著改善结局,临床决策需个体化并等待随机试验。

局限性

  • 原文未报告登记数据的回顾性局限、未校正混杂因素及梗死面积等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Guidelines recommend initiating anticoagulation within 4 to 14 days after cardioembolic stroke. Data supporting this did not account for key factors potentially affecting the decision to initiate anticoagulation, such as infarct size, hemorrhagic transformation, or high-risk features on echocardiography. METHODS: We pooled data from stroke registries of 8 comprehensive stroke centers across the United States. We included consecutive patients admitted with ischemic stroke and atrial fibrillation. The primary predictor was timing of initiating anticoagulation (0-3 days, 4-14 days, or >14 days), and outcomes were recurrent stroke/transient ischemic attack/systemic embolism, symptomatic intracerebral hemorrhage (sICH), and major extracranial hemorrhage (ECH) within 90 days. RESULTS: Among 2,084 patients, 1,289 met the inclusion criteria. The combined endpoint occurred in 10.1% (n = 130) subjects (87 ischemic events, 20 sICH, and 29 ECH). Overall, there was no significant difference in the composite endpoint between the 3 groups (0-3 days: 10.3%, 64/617; 4-14 days: 9.7%, 52/535; >14 days: 10.2%, 14/137; p = 0.933). In adjusted models, patients started on anticoagulation between 4 and 14 days did not have a lower rate of sICH (vs 0-3 days; odds ratio [OR] = 1.49, 95% confidence interval [CI] = 0.50-4.43), nor did they have a lower rate of recurrent ischemic events (vs >14 days; OR = 0.76, 95% CI = 0.36-1.62, p = 0.482). INTERPRETATION: In this multicenter real-world cohort, the recommended (4-14 days) time frame to start oral anticoagulation was not associated with reduced ischemic and hemorrhagic outcomes. Randomized trials are required to determine the optimal timing of anticoagulation initiation. ANN NEUROL 2020;88:807-816.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Yaghi S, Trivedi T, Henninger N, et al. Anticoagulation Timing in Cardioembolic Stroke and Recurrent Event Risk. Ann Neurol. 2020. PMID: 32656768. doi:10.1002/ana.25844

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。